RNAZ

TransCode Therapeutics Inc

1.71

Oct 26 • 3:46 PM ET -0.06 (-3.64%)

1.68

Aftermarket • 5:00 PM ET -0.03 (-1.50%)

Healthcare Biotechnology USA Nano NASD

Today, 8:06 AMTransCode Therapeutics reports Phase 1a TTX-MC138 data in advanced solid tumors meeting primary safety endpoint with no dose-limiting toxicities

Peers: PHIO SLXN SLN IMNN GNPX TOVX ARCT KRRO PRQR MBRX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	28.87M
Enterprise Value	187.19M
Income	-46.28M
Sales	0.00M
Book/sh	-27.38
Cash/sh	0.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Jul 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	3.45
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.97
Current Ratio	1.97
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-50.69
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	96.25% 79.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	86.74%
Sales Y/Y TTM	-
EPS Q/Q	-39.81%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	67.35% -100.00%

Insider Own	5.56%
Insider Trans	0.00%
Inst Own	0.20%
Inst Trans	0.45%
ROA	-53.79%
ROE	-59.28%
ROIC	-30.96%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.13%
SMA50	-12.57%
SMA200	-72.82%
Trades

Shs Outstand	16.93M
Shs Float	15.99M
Short Float	0.33%
Short Ratio	0.98
Short Interest	0.05M
52W High	13.96 -87.78%
52W Low	1.52 12.20%
Volatility	10.47% 10.28%
ATR (14)	0.19
RSI (14)	43.57
Beta	1.25
Rel Volume	1.02
Avg Volume	53.40K
Volume	54,294

Perf Week	0.32%
Perf Month	0.92%
Perf Quarter	-65.89%
Perf Half Y	-79.98%
Perf YTD	-75.03%
Perf Year	-87.26%
Perf 3Y	-99.99%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	1.00
Target Price	280.00
Prev Close	1.77
Price	1.71
Change %	-3.64%

Today 07:31AM	TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 (PR Newswire)
Oct-19-26 08:04AM	TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 (PR Newswire)
Oct-13-26 07:30AM	Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer (Business Wire)
Sep-28-26 08:04AM	TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up (PR Newswire)
Sep-22-26 08:04AM	TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology (PR Newswire)
04:10PM	Loading…
Sep-10-26 04:10PM	TransCode Therapeutics Announces Leadership Transition (PR Newswire) -5.06%
Aug-31-26 08:05AM	TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis (PR Newswire)
Jun-08-26 08:04AM	TransCode Therapeutics to Host R&D Webcast on June 18, 2026 (PR Newswire) -9.11%
Jun-03-26 08:04AM	TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer (PR Newswire)
May-27-26 08:04AM	TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer (PR Newswire) -5.57%
Apr-27-26 08:02AM	TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University (PR Newswire)
Apr-07-26 08:30AM	TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 (PR Newswire)
Mar-03-26 08:01AM	TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients (PR Newswire)
Feb-23-26 08:01AM	TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development (PR Newswire)
Feb-05-26 08:04AM	TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 (PR Newswire) +16.20%
08:01AM	Loading…
Jan-06-26 08:01AM	TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma (PR Newswire)
Dec-22-25 08:01AM	TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors (PR Newswire)
Dec-11-25 08:05AM	TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial (PR Newswire) +20.74%
Nov-17-25 08:01AM	TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer (PR Newswire)
Oct-14-25 08:06AM	TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO (PR Newswire) +5.62%
Oct-08-25 08:01AM	TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company (PR Newswire) +21.11%
May-28-25 08:00AM	TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board (PR Newswire)
May-08-25 08:05AM	TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported (PR Newswire)
May-05-25 05:07PM	TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split (PR Newswire) -17.51% -14.30%
May-02-25 04:10PM	TransCode Therapeutics Announces 1-for-28 Reverse Stock Split (PR Newswire) -9.18%
May-01-25 02:30PM	IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 (NewMediaWire) +38.71%
09:01AM	TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer (PR Newswire)
08:32AM	EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug (Benzinga)
Apr-21-25 04:37PM	TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting (PR Newswire) +10.09%
Apr-18-25 12:00PM	All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy (Zacks)
04:37PM	Loading…
Mar-27-25 04:37PM	TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 (PR Newswire) -11.86% -5.77%
Mar-25-25 06:24PM	TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering (PR Newswire) -14.89%
Mar-23-25 11:11PM	TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Mar-14-25 08:35AM	SRC approves opening of TransCodes fourth cohort in trial of TTX-MC138 (Clinical Trials Arena)
Mar-13-25 07:47AM	TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial (PR Newswire) -27.25%
Feb-25-25 04:15PM	TransCode Therapeutics, Inc. Announces Results of Special Meeting (PR Newswire) -36.73% -21.91%
Feb-06-25 08:00AM	TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial (PR Newswire) +27.18%
Feb-04-25 04:15PM	TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting (PR Newswire) -17.87% +45.13%
Jan-14-25 08:00AM	TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial (PR Newswire) +5.66%
Jan-07-25 08:00AM	Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements (PR Newswire)
Dec-18-24 08:00AM	TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial (PR Newswire) -37.93%
Nov-29-24 04:25PM	TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split (GlobeNewswire) -18.65%
Nov-28-24 07:20AM	Transcode Therapeutics issues 21.2M shares at 37.7c in private placement (TipRanks)
Nov-27-24 07:00AM	TransCode Therapeutics, Inc. Announces $8 Million Private Placement (GlobeNewswire) -8.99%
Nov-26-24 07:05AM	Transcode Therapeutics announces 1-for-33 reverse stock split (TipRanks) +9.59%
Nov-25-24 07:00AM	TransCode Therapeutics Announces 1-for-33 Reverse Stock Split (GlobeNewswire) -10.53%
Nov-12-24 07:00AM	TransCode Therapeutics Open Letter to Shareholders (GlobeNewswire)
Nov-05-24 07:00AM	TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance (GlobeNewswire)
Oct-23-24 07:00AM	TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data (GlobeNewswire) +10.33%
Oct-10-24 07:00AM	TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology (GlobeNewswire) +34.85%
Sep-17-24 07:00AM	TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate (GlobeNewswire) +11.37%
Sep-10-24 07:00AM	TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer (GlobeNewswire)
Sep-05-24 07:00AM	TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate (GlobeNewswire) +16.28%
Aug-15-24 07:00AM	TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation (GlobeNewswire) +9.70%
Jul-24-24 04:05PM	TransCode Therapeutics, Inc. Announces Closing of Public Offering (GlobeNewswire)
Jul-22-24 10:30PM	TransCode Therapeutics, Inc. Announces Pricing of Public Offering (GlobeNewswire) -61.70%
04:07PM	TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-10-24 07:00AM	Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements (GlobeNewswire) +17.27%
Jun-03-24 10:52AM	RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -8.73%
May-29-24 09:15AM	TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 (GlobeNewswire) -25.26%
May-28-24 07:27AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +8.38%
May-13-24 10:20AM	Squarespace (SQSP) Stock Climbs 13% on $6.9 Billion Deal to Go Private (InvestorPlace) -56.30%
08:48AM	Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today? (InvestorPlace)
08:30AM	TransCode Therapeutics Open Letter to Shareholders (GlobeNewswire)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Apr-15-24 09:00AM	TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors (GlobeNewswire) -13.68%
Apr-03-24 09:10AM	TransCode Therapeutics Reports 2023 Results; Provides Business Update (GlobeNewswire)
Mar-28-24 08:30AM	TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer (GlobeNewswire)
Mar-11-24 09:00AM	TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment (GlobeNewswire) -8.60%
Mar-06-24 04:15PM	TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress (GlobeNewswire)
Feb-20-24 08:00AM	TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic (GlobeNewswire)
Jan-31-24 04:05PM	Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market (GlobeNewswire) -7.25%
Jan-29-24 08:30AM	TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer (GlobeNewswire)
Jan-22-24 04:45PM	TransCode Therapeutics Announces Closing of $7.25 Million Public Offering (GlobeNewswire) -6.49%
Jan-19-24 01:09PM	TransCode (RNAZ) Down 50% on Issue of New Common Stock (Zacks) -25.22%
Jan-18-24 01:27PM	TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering (GlobeNewswire) -49.54%
Jan-12-24 04:05PM	TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO (GlobeNewswire) -8.09% -23.80%
Jan-11-24 08:00AM	TransCode Therapeutics Announces 1-for-40 Reverse Stock Split (GlobeNewswire) +10.57%
Jan-04-24 08:05AM	TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives (GlobeNewswire) -8.18%
Dec-12-23 08:30AM	TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138 (GlobeNewswire) -9.38%
Dec-05-23 09:00AM	TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-23 04:10PM	TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Nov-30-23 02:53PM	TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Nov-14-23 04:30PM	TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update (GlobeNewswire) -9.34%
Oct-30-23 04:33PM	TransCode Therapeutics Withdraws Public Offering (GlobeNewswire) +10.36%
Oct-27-23 08:16AM	Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today? (InvestorPlace) -21.61%
08:00AM	Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions (GlobeNewswire)
Oct-26-23 04:19PM	TransCode Therapeutics Announces Public Offering of Common Stock (GlobeNewswire) +12.13%
08:00AM	TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138 (GlobeNewswire)
Oct-24-23 08:00AM	TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138 (GlobeNewswire) +40.39%
Oct-16-23 08:00AM	TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA (GlobeNewswire) +5.84%
Sep-28-23 04:02PM	TransCode Therapeutics Announces Closing of $8.5 Million Public Offering (GlobeNewswire) -12.62%
Sep-25-23 08:01PM	TransCode Therapeutics Announces Pricing of $8 Million Public Offering (GlobeNewswire) +284.04% -72.91%
08:30AM	TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138 (GlobeNewswire)
Aug-23-23 08:00AM	TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial (GlobeNewswire)
Aug-14-23 04:45PM	TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update (GlobeNewswire)
Jul-31-23 07:00AM	TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138 (GlobeNewswire) -5.17%
Jul-13-23 12:43PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi (Newsfile) -6.71%
Jul-10-23 09:55AM	TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jul-05-23 07:00AM	TransCode Therapeutics CEO Letter to Shareholders (GlobeNewswire)

Show Previous News

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. Its lead product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Pharm.Dr. Philippe P. Calais Ph.D.

Scientific Co-Founder & Chief Scientific OfficerDr. Zdravka Medarova Ph.D.

Scientific Co-FounderDr. Anna Moore Ph.D.

Interim Chief Financial OfficerMr. John A. Tattory CPA

Chief Medical OfficerDr. Daniel R. Vlock M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNAZ

TransCode Therapeutics Inc

Upgrade your Finviz experience